PT  - JOURNAL ARTICLE
AU  - Yeung, Cecilia CS
AU  - Sala-Torra, Olga
AU  - Reddy, Shishir
AU  - Hung, Ling-Hong
AU  - Radich, Jerry
AU  - Yeung, Ka Yee
TI  - Ultrarapid Targeted Nanopore Sequencing for Fusion Detection of Leukemias
AID  - 10.1101/2022.06.20.22276664
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.20.22276664
4099  - http://medrxiv.org/content/early/2022/06/23/2022.06.20.22276664.short
4100  - http://medrxiv.org/content/early/2022/06/23/2022.06.20.22276664.full
AB  - Acute leukemia (AL), a cancer of the blood, has continued high mortality rates despite a plethora of available treatments. Variable prognosis, treatment response and survival are largely based on distinct cytogenetic and molecular aberrations that characterize AL subtypes. Fast and cost-effective methods of detecting AL fusions and mutations are needed to improve clinical outcomes for patients. We report preliminary data on an ultrarapid and portable nanopore long-read sequencing assay with a same-day turnaround time of ~6-7 hours for identifying key leukemic fusions. Leukemias frequently present with recurrent fusions that impact risk stratification and therapy choice, our assay can help oncologists overcome time related challenges to get patients on treatments faster.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding is provided in part by NCCN young investigator award and the Hyundai Hope on Wheels Scholars Award, R01 CA175008-06, UG1 CA233338-02, R01GM126019, 75N91021C00022, and 75N91020C00009.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors collectively declare that this research is conducted with approval from the Fred Hutch institutional review board and meets the requirements for ethics approval and consent to participate and consent for publication.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available for review upon request to the corresponding author and the data will be made publicly available upon acceptance.